XBI
SPDR S&P Biotech ETFETF · Themes$156.83−$2.56 (-1.61%)as of market close, Aug 13, 2026
☾ After hours:$156.86+0.00%3:59 PM ET
XBI holdings (2026)
All 148 positions in SPDR S&P Biotech ETF, ranked by portfolio weight — led by RVMD at 2.2%. Weights come from the fund's own SEC N-PORT filing and update daily with prices; positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Weights are the Mar 31, 2026 SEC filing rolled forward on each holding's price move (as of market close, Aug 13, 2026) — an estimate of today, not the filed figure. Switch the table below to see them exactly as filed.
Holdings
148
positions in the latest filing
Largest holding
2.2%
RVMD · estimated today
Top 10 weight
16%
concentration · estimated today
On ChartRow
32.5%
fund weight in tickers ChartRow tracks
Filed
Mar 31, 2026
SEC N-PORT report date
Top 10 holdings#
CompanyWeight1D
3Apellis Pharmaceuticals Inc
1.7%—
7Alkermes PLC
1.4%—
Sector weights#
SectorWeight
Not on ChartRow
67.5%
Healthcare
32.5%
XBI holdings by weight#
1–100 of 148Weightsthe Mar 31, 2026 filing rolled forward on price — an estimate (as of market close, Aug 13, 2026)
| # | Company | Weight | Price | 1D | YTD | 1Y | Mkt cap |
|---|---|---|---|---|---|---|---|
| 1 | RVMDRevolution Medicines Inc. | 2.20% | $201.93 | -1.6% | +153.5% | +472.7% | $43B |
| 2 | APGEApogee Therapeutics Inc. | 1.96% | $134.42 | -0.1% | +78.1% | +266.3% | $10B |
| 3 | Apellis Pharmaceuticals Inc | 1.75% | — | — | — | — | — |
| 4 | NTRANatera Inc. | 1.72% | $310.78 | -1.6% | +35.7% | +94.5% | $45B |
| 5 | HALOHalozyme Therapeutics Inc. | 1.64% | $100.67 | -1.1% | +49.6% | +57.2% | $11B |
| 6 | ARWRArrowhead Pharmaceuticals Inc. | 1.60% | $85.63 | -1.9% | +29.0% | +381.1% | $12B |
| 7 | Alkermes PLC | 1.38% | — | — | — | — | — |
| 8 | INCYIncyte Corp. | 1.38% | $120.49 | -0.2% | +22.0% | +47.6% | $24B |
| 9 | PRAXPraxis Precision Medicines Inc. | 1.35% | $368.47 | -4.6% | +25.0% | +660.4% | $10B |
| 10 | ROIVRoivant Sciences Ltd. | 1.33% | $36.29 | +0.4% | +67.2% | +213.7% | $26B |
| 11 | EXELExelixis Inc. | 1.32% | $50.59 | +0.4% | +15.4% | +33.3% | $13B |
| 12 | TG Therapeutics Inc | 1.29% | — | — | — | — | — |
| 13 | MDGLMadrigal Pharmaceuticals Inc. | 1.28% | $507.08 | -5.4% | -12.9% | +41.2% | $12B |
| 14 | NBIXNeurocrine Biosciences Inc. | 1.26% | $150.80 | -3.6% | +6.3% | +17.0% | $15B |
| 15 | CYTKCytokinetics Incorporated | 1.25% | $73.44 | -2.9% | +15.6% | +114.0% | $10B |
| 16 | Scholar Rock Holding Corp | 1.24% | — | — | — | — | — |
| 17 | BBIOBridgeBio Pharma Inc. | 1.24% | $81.22 | -3.1% | +6.2% | +65.5% | $16B |
| 18 | MRNAModerna Inc. | 1.24% | $63.65 | -0.0% | +115.8% | +148.1% | $25B |
| 19 | BMRNBioMarin Pharmaceutical Inc. | 1.23% | $68.50 | -2.5% | +15.3% | +20.5% | $13B |
| 20 | AMGNAmgen Inc. | 1.20% | $417.93 | +0.4% | +27.7% | +46.7% | $226B |
| 21 | BIIBBiogen Inc. | 1.20% | $210.61 | +0.8% | +19.7% | +63.4% | $31B |
| 22 | ABBVAbbVie Inc. | 1.20% | $250.84 | +0.8% | +9.8% | +26.3% | $443B |
| 23 | Protagonist Therapeutics Inc | 1.19% | — | — | — | — | — |
| 24 | Cogent Biosciences Inc | 1.16% | — | — | — | — | — |
| 25 | VRTXVertex Pharmaceuticals Incorporated | 1.14% | $516.13 | -1.8% | +13.8% | +33.1% | $131B |
| 26 | REGNRegeneron Pharmaceuticals Inc. | 1.13% | $805.82 | +1.0% | +4.4% | +44.8% | $83B |
| 27 | PTC Therapeutics Inc | 1.13% | — | — | — | — | — |
| 28 | Nuvalent Inc | 1.11% | — | — | — | — | — |
| 29 | Kymera Therapeutics Inc | 1.11% | — | — | — | — | — |
| 30 | CG oncology Inc | 1.11% | — | — | — | — | — |
| 31 | Twist Bioscience Corp | 1.10% | — | — | — | — | — |
| 32 | Krystal Biotech Inc | 1.10% | — | — | — | — | — |
| 33 | Vaxcyte Inc | 1.10% | — | — | — | — | — |
| 34 | Mirum Pharmaceuticals Inc | 1.09% | — | — | — | — | — |
| 35 | Amicus Therapeutics Inc | 1.09% | — | — | — | — | — |
| 36 | Ionis Pharmaceuticals Inc | 1.09% | — | — | — | — | — |
| 37 | Travere Therapeutics Inc | 1.09% | — | — | — | — | — |
| 38 | Arcellx Inc | 1.09% | — | — | — | — | — |
| 39 | Celcuity Inc | 1.07% | — | — | — | — | — |
| 40 | Rhythm Pharmaceuticals Inc | 1.05% | — | — | — | — | — |
| 41 | Arcutis Biotherapeutics Inc | 1.04% | — | — | — | — | — |
| 42 | CRISPR Therapeutics AG | 1.03% | — | — | — | — | — |
| 43 | GILDGilead Sciences Inc. | 1.03% | $138.14 | +1.7% | +12.5% | +15.1% | $171B |
| 44 | ImmunityBio Inc | 1.01% | — | — | — | — | — |
| 45 | UTHRUnited Therapeutics Corporation | 1.00% | $501.11 | -2.1% | +2.8% | +66.3% | $21B |
| 46 | Beam Therapeutics Inc | 0.99% | — | — | — | — | — |
| 47 | Viking Therapeutics Inc | 0.99% | — | — | — | — | — |
| 48 | Vera Therapeutics Inc | 0.99% | — | — | — | — | — |
| 49 | INSMInsmed Incorporated | 0.98% | $126.31 | -4.5% | -27.4% | +3.5% | $28B |
| 50 | Erasca Inc | 0.98% | — | — | — | — | — |
| 51 | ACADIA Pharmaceuticals Inc | 0.97% | — | — | — | — | — |
| 52 | SMMTSummit Therapeutics Inc. Common Stock | 0.87% | $14.00 | -7.3% | -20.0% | -45.5% | $11B |
| 53 | Sarepta Therapeutics Inc | 0.85% | — | — | — | — | — |
| 54 | Agios Pharmaceuticals Inc | 0.84% | — | — | — | — | — |
| 55 | Ultragenyx Pharmaceutical Inc | 0.83% | — | — | — | — | — |
| 56 | Disc Medicine Inc | 0.83% | — | — | — | — | — |
| 57 | Immunome Inc | 0.82% | — | — | — | — | — |
| 58 | Immunovant Inc | 0.82% | — | — | — | — | — |
| 59 | BioCryst Pharmaceuticals Inc | 0.81% | — | — | — | — | — |
| 60 | Veracyte Inc | 0.81% | — | — | — | — | — |
| 61 | Dyne Therapeutics Inc | 0.80% | — | — | — | — | — |
| 62 | ALNYAlnylam Pharmaceuticals Inc. | 0.77% | $227.00 | +1.4% | -42.9% | -47.2% | $30B |
| 63 | Catalyst Pharmaceuticals Inc | 0.72% | — | — | — | — | — |
| 64 | Syndax Pharmaceuticals Inc | 0.70% | — | — | — | — | — |
| 65 | Denali Therapeutics Inc | 0.70% | — | — | — | — | — |
| 66 | Ideaya Biosciences Inc | 0.70% | — | — | — | — | — |
| 67 | Spyre Therapeutics Inc | 0.69% | — | — | — | — | — |
| 68 | GRAIL Inc | 0.69% | — | — | — | — | — |
| 69 | Viridian Therapeutics Inc | 0.67% | — | — | — | — | — |
| 70 | Recursion Pharmaceuticals Inc | 0.66% | — | — | — | — | — |
| 71 | Kodiak Sciences Inc | 0.66% | — | — | — | — | — |
| 72 | Soleno Therapeutics Inc | 0.64% | — | — | — | — | — |
| 73 | Dianthus Therapeutics Inc | 0.63% | — | — | — | — | — |
| 74 | Intellia Therapeutics Inc | 0.62% | — | — | — | — | — |
| 75 | Mineralys Therapeutics Inc | 0.62% | — | — | — | — | — |
| 76 | Arcus Biosciences Inc | 0.60% | — | — | — | — | — |
| 77 | Ardelyx Inc | 0.59% | — | — | — | — | — |
| 78 | ADMA Biologics Inc | 0.57% | — | — | — | — | — |
| 79 | Nurix Therapeutics Inc | 0.56% | — | — | — | — | — |
| 80 | Tango Therapeutics Inc | 0.53% | — | — | — | — | — |
| 81 | Celldex Therapeutics Inc | 0.50% | — | — | — | — | — |
| 82 | Novavax Inc | 0.49% | — | — | — | — | — |
| 83 | Oruka Therapeutics Inc | 0.48% | — | — | — | — | — |
| 84 | Olema Pharmaceuticals Inc | 0.47% | — | — | — | — | — |
| 85 | Stoke Therapeutics Inc | 0.47% | — | — | — | — | — |
| 86 | Vericel Corp | 0.46% | — | — | — | — | — |
| 87 | Capricor Therapeutics Inc | 0.46% | — | — | — | — | — |
| 88 | Palvella Therapeutics Inc | 0.44% | — | — | — | — | — |
| 89 | Biohaven Ltd | 0.42% | — | — | — | — | — |
| 90 | Monte Rosa Therapeutics Inc | 0.41% | — | — | — | — | — |
| 91 | Corvus Pharmaceuticals Inc | 0.40% | — | — | — | — | — |
| 92 | Iovance Biotherapeutics Inc | 0.37% | — | — | — | — | — |
| 93 | AnaptysBio Inc | 0.36% | — | — | — | — | — |
| 94 | Relay Therapeutics Inc | 0.36% | — | — | — | — | — |
| 95 | uniQure NV | 0.36% | — | — | — | — | — |
| 96 | ORIC Pharmaceuticals Inc | 0.35% | — | — | — | — | — |
| 97 | MannKind Corp | 0.34% | — | — | — | — | — |
| 98 | CareDx Inc | 0.33% | — | — | — | — | — |
| 99 | Taysha Gene Therapies Inc | 0.32% | — | — | — | — | — |
| 100 | Tyra Biosciences Inc | 0.32% | — | — | — | — | — |
Methodology#
Holdings and weights are sourced from the fund's portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding's price move, keeping the numbers current between filings; positions in stocks ChartRow doesn't track carry their filed weight unchanged and show "—" where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet's GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of XBI?
- XBI's top 10 holdings are Revolution Medicines Inc. (RVMD), 2.2%; Apogee Therapeutics Inc. (APGE), 2.0%; Apellis Pharmaceuticals Inc, 1.7%; Natera Inc. (NTRA), 1.7%; Halozyme Therapeutics Inc. (HALO), 1.6%; Arrowhead Pharmaceuticals Inc. (ARWR), 1.6%; Alkermes PLC, 1.4%; Incyte Corp. (INCY), 1.4%; Praxis Precision Medicines Inc. (PRAX), 1.3%; Roivant Sciences Ltd. (ROIV), 1.3% — together about 16% of the fund, per its Mar 31, 2026 SEC filing with weights rolled forward to today.
- How many holdings does XBI have?
- SPDR S&P Biotech ETF (XBI) held 148 positions as of its latest SEC N-PORT filing (Mar 31, 2026).
- How current are XBI's holdings?
- Funds disclose their full portfolio to the SEC on Form N-PORT; the quarter-end report becomes public about 60 days later. ChartRow anchors on the latest public filing (Mar 31, 2026) and rolls each weight forward daily by that holding's price move, so the weights shown estimate today rather than the filing date.
- Is ChartRow affiliated with XBI or State Street?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by State Street or SPDR S&P Biotech ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.